In a Phase III randomised placebo-controlled study, addition of midostaurin to induction and consolidation chemotherapy, followed by maintenance treatment in FLT3-mutated AML was shown to improve overall survival [2]. The gene discussed is FLT3; the disease is acute myeloid leukemia.